Zevra Therapeutics, Inc.
ZVRA
$8.33
-$0.06-0.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 139.40% | 103.96% | -86.01% | -129.13% | -339.38% |
| Total Depreciation and Amortization | -3.40% | 65.24% | 160.18% | 535.09% | 965.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -325.85% | -1,252.24% | 1,343.47% | 541.72% | 236.58% |
| Change in Net Operating Assets | -387.04% | -628.80% | -956.74% | -212.87% | -136.68% |
| Cash from Operations | 66.42% | 17.56% | -35.19% | -107.74% | -218.57% |
| Capital Expenditure | -1,102.78% | -27.87% | 62.92% | -- | 72.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -47.86% | -222.72% | -157.67% | -266.54% | 187.72% |
| Cash from Investing | 303.59% | 25.29% | -276.57% | -27.44% | 78.23% |
| Total Debt Issued | -100.00% | -100.00% | 95.21% | 37.51% | 59.03% |
| Total Debt Repaid | 99.22% | 99.22% | -790.91% | -138.29% | -246.78% |
| Issuance of Common Stock | -85.27% | 777.42% | 802.00% | 963.54% | 22,091.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -- | -- | -3,175.00% |
| Cash from Financing | -88.05% | 43.38% | 146.77% | 188.46% | 272.00% |
| Foreign Exchange rate Adjustments | 673.48% | -10.56% | 292.42% | 931.82% | 213.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -96.29% | 131.38% | -306.48% | 58.67% | 140.20% |